IVD MEDICAL (01931) announced that the company and its subsidiaries ETHK Inc and ETHK HOLDINGS LIMITED have entered into a strategic cooperation agreement with Transcenta Holding Limited (TRANSCENTA, stock code: 06628.HK) and its subsidiary Transcenta Oncology Inc. (US) (collectively referred to as the Transcenta parties) regarding potential RWA tokenization of innovative drug pipeline assets.
Under this agreement, the Transcenta parties will integrate six core innovative drug pipeline assets (namely TST003, TST005, TST786, TST105, TST106, and TST013) into their US entity Transcenta Oncology Inc. (US), and collaborate with IVD MEDICAL on potential RWA tokenization of these assets using the group's professionally constructed ETHK Global Innovative Drug Intellectual Property RWA Exchange.
These assets have a total estimated value exceeding $1.5 billion, representing the most cutting-edge research directions and high technical barriers in the global oncology treatment field. The group will provide comprehensive technical solutions for these pipeline assets, covering digital initiation, trusted on-chain processes, compliant issuance, and liquidity connectivity.
This collaboration marks the first official launch of high-value innovative drug intellectual property assets in RWA form in capital markets, representing a milestone event that signifies the deep integration of technology and finance.
The six innovative drug pipelines that will explore potential RWA tokenization cover multiple cutting-edge technology platforms including bispecific antibodies, trispecific antibodies, ADC, and fusion proteins, with each pipeline having First-in-Class or Best-in-Class potential globally.
Upon successful completion of this collaboration, it will not only represent an on-chain asset issuance but also a transformation of traditional R&D financing and value realization models in the biopharmaceutical industry.
Through RWA tokenization, the partnership aims to:
Lock in R&D value for high-value pipelines in advance: Enabling issuers to efficiently monetize their top-tier pipeline assets at different clinical stages, injecting innovative funding for subsequent R&D without equity dilution.
Provide new global capital allocation channels: Offering global professional investors a rare opportunity for transparent, compliant, and efficient allocation to the world's most cutting-edge innovative drug intellectual property assets, sharing in biotechnology breakthrough dividends.
Accelerate therapy accessibility: Accelerating the R&D process of cutting-edge therapies through innovative financing models, ultimately benefiting global patients and meeting urgent unmet medical needs.
The announcement states that this collaboration will generate significant synergistic effects, injecting strong momentum for the group's future sustainable business growth and financial performance. The group will work closely with the Transcenta parties to ensure the high-standard successful implementation of this project.
